Skip to main content
SpringerLink
Log in

Clinical Significance of Antimicrobial Resistance

  • Conference paper
Yearbook of Intensive Care and Emergency Medicine 1999

Part of the book series: Yearbook of Intensive Care and Emergency Medicine ((YEARBOOK,volume 1999))

  • 237 Accesses

Abstract

Antimicrobial resistance is an increasing problem. There are now microorganisms resistant to all available treatment options [1–8]. Important antimicrobial resistance problems in Gram-positive bacteria include penicillin resistance in Streptococcus pneumoniae, vancomycin and multiple drug resistance in enterococci, and methicillin resistance, and reduced susceptibility of staphylococci to the glycopeptides. In Gram-negative bacteria extended spectrum beta-lactamases and inducible beta-lactamases, particularly in Enterobacter, Escherichia coli and Klebsiella species, have been of greatest concern.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen ML (1992) Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050–1055.

    Article  PubMed  CAS  Google Scholar 

  2. Moberg CL (1996) René Dubos: A harbinger of microbial resistance to antibiotics. Microb Drug Resist 2:287–297.

    Article  PubMed  CAS  Google Scholar 

  3. Falkow S (1998) The microbe’s view of infection. Ann Intern Med 129:247–248.

    PubMed  CAS  Google Scholar 

  4. Kunin CM (1993) Resistance to antimicrobial drugs-a worldwide calamity. Ann Intern Med 118:557–561.

    PubMed  CAS  Google Scholar 

  5. Neu HC (1992) The crisis in antibiotic resistance. Science 257:1064–1072.

    Article  PubMed  CAS  Google Scholar 

  6. Levy SB (1993) Confronting multidrug resistance: a role for each of us. JAMA 269:1840–1842.

    Article  PubMed  CAS  Google Scholar 

  7. Murray BE (1992) Problems and dilemmas of antimicrobial resistance. Pharmacother. 12: 86S–93S.

    CAS  Google Scholar 

  8. Snydman DR (1991) Clinical implications of multi-drug resistance in the intensive care unit. Scand J Infect Dis 78:54–63.

    CAS  Google Scholar 

  9. Gold HS, Moellering RC, Jr (1996) Antimicrobial drug resistance. Drug Therapy 335:1445–1453.

    CAS  Google Scholar 

  10. Flaherty JP, Weinstein RA (1996) Nosocomial infection caused by antibiotic resistant organisms in the intensive care unit. Infect Control Hosp Epidemiol 17:236–248.

    Article  PubMed  CAS  Google Scholar 

  11. Holmberg SD, Solomon SL, Blake PA (1987) Health and economic impacts of antimicrobial resistance. Rev Infect Dis 9:1065–1078.

    Article  PubMed  CAS  Google Scholar 

  12. Boyce JM, Landry M, Deetz TR, DuPont HL (1981) Epidemiologic studies of an outbreak of nosocomial methicillin resistant Staphylococcus aureus infections. Infect Control 2:110–116.

    PubMed  CAS  Google Scholar 

  13. Landry SL, Kaiser DL, Wenzel RP (1989) Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control 17:323–329.

    Article  PubMed  CAS  Google Scholar 

  14. Jernigan DB, Cetron MS, Breiman RF (1996) Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). JAMA 275:206–209.

    Article  PubMed  CAS  Google Scholar 

  15. Linares J, Pallares R, Alonso T, et al (1992) Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979–1990). Clin Infect Dis 15:99–105.

    Article  PubMed  CAS  Google Scholar 

  16. Verhaegen J, Glupczynski Y, Verbist L, et al (1995) Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980–1993. Clin Infect Dis 20:1339–1345.

    Article  PubMed  CAS  Google Scholar 

  17. Koornhof HJ, Wasas A, Klugman K (1992) Antimicrobial resistance in Streptococcus pneumoniae: A South African perspective. Clin Infect Dis 15:84–94.

    Article  PubMed  CAS  Google Scholar 

  18. Plouffe JF, Breiman RF, Facklam RR (1996) Bacteremia with Streptococcus pneumoniae. JAMA 275:194–198.

    Article  PubMed  CAS  Google Scholar 

  19. Centers for Disease control, CDC surveillance summaries (1986) National nosocomial infection surveillance, 1984. Morb Mortal Wkly Rep 35: (suppl): 17ss–29ss.

    Google Scholar 

  20. Murray BE (1990) The life and times of the enterococcus. Clin Microbiol Rev 3:46–65.

    PubMed  CAS  Google Scholar 

  21. Centers for Disease Control and Prevention (1993) Nosocomial enterococci resistant to vancomycin-United States, 1989–1993. Morb Mortal Wkly Rep 42:597–599.

    Google Scholar 

  22. Zervos MJ, Kauffman CA, Therasse P, Bergman A, Mikesell TS, Schaberg DR (1987) Nosocomial infection caused by gentamicin resistant Streptococcus faecalis: an epidemiologic study. Ann Intern Med 106:687–691.

    PubMed  CAS  Google Scholar 

  23. Patterson JE, Zervos MJ (1990) High level gentamicin resistance in enterococci: epidemiology, microbiology and genetic basis. Rev Infect Dis 12:644–652.

    Article  PubMed  CAS  Google Scholar 

  24. Schaberg DR, Zervos MJ (1986) Intergenic and interspecies gene exchange in Gram-positive cocci. Antimicrob Agents Chemother 39:817–822.

    Article  Google Scholar 

  25. Thal LA, Chow JW, Clewell DB, Zervos MJ (1994) Tn924, a chromosome-borne transposon encoding high-level gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother 38:1152–1156.

    Article  PubMed  CAS  Google Scholar 

  26. Hanrahan JA, Hoyen C, Rice LB (1998) Evidence for the geographic dispersion of a transferable mobile element conferring resistance to ampicillin and vancomycin in VanB E. faecium. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA (Abst).

    Google Scholar 

  27. Hodel-Christian SL, Murray BE (1991) Characterization of the gentamicin resistance transposon Tn5281 from Enterococcus faecalis and comparison to staphylococcal transposons Tn4001 and Tn4031. Antimicrob Agents Chemother 35:1147–1152.

    Article  PubMed  CAS  Google Scholar 

  28. Chow JW, Zervos MJ, Lerner SA, et al (1997) A novel gentamicin resistance gene in Enterococcus. Antimicrob Agents Chemother 341:511–514.

    Google Scholar 

  29. Tsai SF, Zervos MJ, Clewell DB, Donabedian SM, Sahm DF, Chow JW (1998) A new high-level gentamicin resistance gene, aph(2″)-Id, in Enterococcus spp. Antimicrob Agents Chemother 42:1229–1232.

    PubMed  CAS  Google Scholar 

  30. Leclercq R, Derlot E, Duval J, Courvalin P (1988) Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 319:157–161.

    Article  PubMed  CAS  Google Scholar 

  31. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC (1993) Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 37:2311–2317.

    Article  PubMed  CAS  Google Scholar 

  32. Arthur M, Courvalin P (1993) Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37:1563–1571.

    Article  PubMed  CAS  Google Scholar 

  33. Silverman J, Thal LA, Perri MB, Bostic G, Zervos MJ (1998) Epidemiologic evaluation of antimicrobial resistance in community acquired enterococci. J Clin Microbiol 36:830–832.

    PubMed  CAS  Google Scholar 

  34. Boyce JM, Mermel LA, Zervos MJ, et al (1995) Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 16:634–637.

    Article  PubMed  CAS  Google Scholar 

  35. Thal L, Donabedian SM, Robinson-Dunn B, et al (1998) Molecular analysis of glycopeptide-resistant Enterococcus faecium isolates collected from Michigan hospitals over a 6-year period. J Clin Microbiol 36:3303–3308.

    PubMed  CAS  Google Scholar 

  36. Vo HK, Zervos MJ (1999) Commentary: quinupristin/dalfopristin for therapy of serious gram-positive infection. Infect Dis Clin Pract (in press).

    Google Scholar 

  37. Aeschlimann JR, Zervos MJ, Rybak MJ (1998) Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin/dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob Agents Chemother 42:2710–2717.

    PubMed  CAS  Google Scholar 

  38. Bonilla HF, Perri MB, Kauffman CA, Zervos MJ (1996) Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diag Microbiol Infect Dis 25:127–131.

    Article  CAS  Google Scholar 

  39. Welton LA, Thal LA, Perri MB, Donabedian SM, et al (1998) Antimicrobial resistance in enterococci isolated from turkey flocks fed virginiamycin. Antimicrob Agents Chemother 42:705–708.

    PubMed  CAS  Google Scholar 

  40. Perri MB, Chow JW, Zervos MJ (1993) In vitro susceptibility of sparfloxacin and clinafloxacin versus multi-drug resistant enterococci. Diag Microbiol Infect Dis 17:151–155.

    Article  CAS  Google Scholar 

  41. Bostic GD, Perri MB, Thal LA, Zervos MJ (1997) Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multi-drug resistant enterococci. Diag Microbiol Infect Dis 30:109–112.

    Article  Google Scholar 

  42. Hayden MK, Trenholme GM, Schultz JE, Sahm DF (1993) In vivo development of teicoplanin resistance in a van B Enterococcus faecium isolate. J Infect Dis 167:1225–1227.

    Article  Google Scholar 

  43. Schwalbe RS, Stapleton JT, Gilligan PH (1987) Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316:927–931.

    Article  PubMed  CAS  Google Scholar 

  44. Centers for Disease Control (1997) Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. Morb Mortal Wkly Rep 46:624–624.

    Google Scholar 

  45. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135–136.

    Article  PubMed  CAS  Google Scholar 

  46. Robinson-Dunn B, Jennings G, Mitchell J, et al (1997) Characterization of a unique isolate of vancomycin-intermediate Staphylococcus aureus (VISA). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, CA (Abst).

    Google Scholar 

  47. Centers for Disease Control (1997) Staphylococcus aureus with reduced susceptibility to vancomycin-United States. Morb Mortal Wkly Rep 46:813–814.

    Google Scholar 

  48. Mainardi J-I, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW (1995) Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 171:1646–1650.

    Article  PubMed  CAS  Google Scholar 

  49. Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP (1990) Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 28:2064–2068.

    PubMed  CAS  Google Scholar 

  50. Biavasco F, Giovanetti E, Montanari MP, Lupidi R, Varaldo PE (1991) Development of in vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother 27:71–79.

    Article  PubMed  CAS  Google Scholar 

  51. Daum RS, Gupta S, Sabbagh R, Milewski WM (1992) Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 166:1066–1072.

    Article  PubMed  CAS  Google Scholar 

  52. Kaatz GW, Seo SM, Dorman NJ, Lerner SA (1990) Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 162:103–108.

    Article  PubMed  CAS  Google Scholar 

  53. Sieradzki K, Tomasz A (1996) A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiol Lett 142:161–166.

    Article  PubMed  CAS  Google Scholar 

  54. Milewski WM, Boyle-Vavra S, Moreira B, Ebert CC, Daum RS (1996) Overproduction of a 37-kilodalton cytoplasmic protein hemologous to NAD +-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 40:166–172.

    PubMed  CAS  Google Scholar 

  55. Edmond MB, Wenzel RP, Pasculle AW (1996) Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 124:329–334.

    PubMed  CAS  Google Scholar 

  56. Jacoby G, Bush K (1997) Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant beta-lactamases. Available at: http://www.lahey.org/studies/webt.htm.

  57. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211–1233.

    Article  PubMed  CAS  Google Scholar 

  58. Medeiros AA (1997) Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 24(suppl 1): S19–S45.

    Article  PubMed  CAS  Google Scholar 

  59. Philippon A, Arlet G, Lagrange PH (1994) Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 13(suppl 1): S17–S29.

    Article  PubMed  Google Scholar 

  60. Livermore DM (1995) Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584.

    PubMed  CAS  Google Scholar 

  61. Vahaboglu H, Ozturk R, Aygun G, et al (1997) Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 41:2265–2269.

    PubMed  CAS  Google Scholar 

  62. Danel F, Hall LM, Gur D, Livermore DM (1995) OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 39:1881–1884.

    Article  PubMed  CAS  Google Scholar 

  63. Baurnfeind A, Stemplinger I, Jungwirth R, Wilhelm R, Chong Y (1996) Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes. Antimicrob Agents Chemother 40:1926–1930.

    Google Scholar 

  64. Sanders CC, Sanders WE, Jr (1986) Microbial resistance to newer generation β-lactam antibiotics: clinical and laboratory implications. J Infect Dis 151:399–406.

    Article  Google Scholar 

  65. Sanders CC, Sanders WE, Jr (1986) Type I β-lactamases of Gram-negative bacteria: interactions with β-lactam antibiotics. J Infect Dis 154:792–800.

    Article  PubMed  CAS  Google Scholar 

  66. Thornsberry C (1996) Emerging resistance in clinically important Gram-positive cocci. West J Med 164:28–32.

    PubMed  CAS  Google Scholar 

  67. Chow JW, Fine MJ, Shlaes DM, et al (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585–590.

    PubMed  CAS  Google Scholar 

  68. Livermore DM (1991) Mechanisms of resistance to β-lactam antibiotics. Scand J Infect Dis 78:7–16.

    CAS  Google Scholar 

  69. Sanders CC, Sanders WE, Jr (1992) β-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 15:824–839.

    Article  PubMed  CAS  Google Scholar 

  70. Jacoby GA (1994) Genetics of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 13:S2–Sll.

    Article  PubMed  Google Scholar 

  71. Burwen DR, Banerjee SN, Gaynes RP (1994) Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 170:1622–1625.

    Article  PubMed  CAS  Google Scholar 

  72. Quinn JP (1994) Clinical significance of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 13: S39–S42.

    Article  PubMed  Google Scholar 

  73. Eliopolous GM, Wennersten CB, Gold HS, Moellering RC, Jr (1996) In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 40: 1745–1747.

    Google Scholar 

  74. Jones RN, Barrett MS, Erwin ME (1996) In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 41:488–493.

    Google Scholar 

  75. Kaatz GW, Seo SM (1996) In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 40:799–801.

    PubMed  CAS  Google Scholar 

  76. Goldmann DA, Weinstein RA, Wenzel RP, et al (1996) Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 275:234–240.

    Article  PubMed  CAS  Google Scholar 

  77. Seppälä H, Klaukka T, Varkila-Vuopio J, et al (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 337:441–446.

    Article  PubMed  Google Scholar 

  78. Price J, Ekleberry A, Melendy S, et al (1999) Evaluation of clinical practice guidelines on outcome of infection in surgical intensive care unit patients. Crit Care Med (in press).

    Google Scholar 

  79. Brooks A, Ekleberry A, McMahon J, et al (1999) Evaluation of clinical practice guidelines on outcome of infection in medical intensive care unit patients. Infect Dis Clin Pract (in press).

    Google Scholar 

  80. Baddam K, Brooks A, VanDam D, Zervos MJ (1998) Cefepime vs. ceftazidime for therapy of serious lower respiratory tract infection. 36th Annual Meeting IDSA, Denver (Abst).

    Google Scholar 

Download references

Authors
  1. M. Ionescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. J. Zervos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent (Clinical Director) (Clinical Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Ionescu, M., Zervos, M.J. (1999). Clinical Significance of Antimicrobial Resistance. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1999. Yearbook of Intensive Care and Emergency Medicine, vol 1999. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-13453-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-13453-5_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-65288-5

  • Online ISBN: 978-3-662-13453-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation